Start the conversation
Organovo Holdings Inc. (NYSE: ONVO) develops human tissue used for drug development and biological research. It also makes therapeutic implants that treat damaged organs and tissue.
It makes the tissue with a new technology called 3D Bioprinting, which identifies key architectural and compositional elements of a target tissue and then creates a design that can be utilized by a 'bioprinter' to generate that tissue in the laboratory.
ONVO has collaboration agreements with numerous institutes and private companies like the United Therapeutics Corporation, the Knight Cancer Institute, and the Michael J. Fox Foundation, among others.
Organovo is a development-stage company currently trading at $3.38, with a market cap just under $300 million.